NEUROONE MEDICAL TECHNOLOGIES CorpNMTC
Price (close)
$1.33
Market cap
$11.6M
P/E
—
Revenue (TTM)
$9.5M
Net income
-$7.4M
Dividend yield
—
1-year total return
-75.3%
Net margin
-78.6%
Revenue growth
42.8%
Debt / equity
—
What NEUROONE MEDICAL TECHNOLOGIES Corp does.
(i) diagnostic, ablation and deep brain stimulation technology for brain related conditions such as epilepsy and Parkinson’s disease;
(ii) ablation and stimulation for pain management throughout the body; and (iii) drug delivery including diagnostic and stimulation capabilities.
our devices from the Food and Drug Administration (“FDA”), including: (i) our Evo cortical electrode technology for temporary
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $178,146 | $171,169 | $2.0M | $3.5M | $9.1M |
| Net income | -$13.6M | -$9.9M | -$10.0M | -$11.9M | -$12.3M | -$3.6M |
| Free cash flow | -$3.5M | -$8.7M | -$7.8M | -$13.3M | -$11.1M | -$2.9M |
More on NMTC.
- NEUROONE MEDICAL TECHNOLOGIES Corp summary
- NEUROONE MEDICAL TECHNOLOGIES Corp financial statements
- NEUROONE MEDICAL TECHNOLOGIES Corp key metrics
- NEUROONE MEDICAL TECHNOLOGIES Corp health scores and style box
- NEUROONE MEDICAL TECHNOLOGIES Corp earnings
- NEUROONE MEDICAL TECHNOLOGIES Corp dividends
- NEUROONE MEDICAL TECHNOLOGIES Corp valuation
- NEUROONE MEDICAL TECHNOLOGIES Corp ownership and insiders
- NEUROONE MEDICAL TECHNOLOGIES Corp peers
Figures from NEUROONE MEDICAL TECHNOLOGIES Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.